The role of DNA methylation in aging, rejuvenation, and age-related disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without systematic review methods or new empirical human data.
PubMed 23098078 · doi:10.1089/rej.2012.1324
What was done
This is a narrative review describing the mechanisms of DNA methylation governed by DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) and summarizing how alterations in 5-methylcytosine patterns associate with aging, age-related pathologies (such as cancer, osteoarthritis, and neurodegeneration), and potential epigenetic therapies.
What was found
The abstract reports no quantitative data, statistics, effect sizes, or sample counts. It describes qualitative patterns, noting that aging is generally characterized by genome-wide hypomethylation accompanied by promoter-specific hypermethylation, and mentions that DNMT-targeting drugs such as 5-azacytidine are being evaluated in clinical trials.
Why it matters
It outlines how reversible epigenetic modifications contribute to age-related disease and discusses the theoretical basis for using DNA methyltransferase modulators in rejuvenation research and disease management.
Limits
As a broad narrative review, the paper does not employ systematic review methodology, provides no quantitative synthesis or risk-of-bias assessments, and relies on descriptive mechanistic overviews rather than primary empirical data.
Cited by
- supports Aging causes the DNA methylation landscape across the genome to flatten out through gain of methylation at normally unmethylated sites and loss of methylation at normally hypermethylated sites.